- Home
- SATL vs PACB Comparison
SATL vs PACB Comparison
Compare SATL & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SATL | PACB |
|---|---|---|
| Founded | 2010 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.3M | 486.1M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SATL | PACB |
|---|---|---|
| Price | $3.17 | $1.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $6.00 | $2.20 |
| AVG Volume (30 Days) | 4.6M | ★ 6.1M |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $16.18 | $12.46 |
| Revenue Next Year | $92.36 | $12.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $1.26 | $0.85 |
| 52 Week High | $5.93 | $2.73 |
Technical Indicators
Market Signals| Indicator | SATL | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 46.96 | 37.08 |
| Support Level | $2.73 | $1.36 |
| Resistance Level | $3.94 | $1.73 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 36.45 | 2.94 |
Price Performance
Historical ComparisonAbout SATL Satellogic Inc.
Satellogic Inc is a provider of satellite imagery to governments and commercial customers globally. It geographically operates in North America, Europe, Asia and South America. It derives maximum revenue from Asia Pacific.
About PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.